Berberine LipoMicel

Berberine LipoMicel Higher Bioavailability – 500 mg, 60 Liquid Softgels (SKU: 9214, NPN: 80121912)

Benefits

• High Potency: Provides 500 mg of berberine HCl per softgel, the dosing strength used in clinical trials for glucose and lipid control.
• Advanced Technology: Utilizes LipoMicel technology to create a liquid micelle matrix that disperses berberine into tiny microdroplets, resulting in higher absorption compared to standard forms.
• Metabolic Support: Supports healthy glucose metabolism via multiple mechanisms, including enhancement of insulin sensitivity.
• Lipid Management: Positively impacts blood lipids, reducing triglycerides, total cholesterol, and LDL cholesterol.
• Antioxidant Activation: Activates Nrf-2, a key regulator of antioxidant gene transcription and prevention of glucose-induced neurotoxicity.
• Cardiovascular Health: Helps maintain cardiovascular health.
• Natural Source: Extracted from Berberis vulgaris (European barberry).

Feature Summary

While traditionally used for gastrointestinal symptoms, current research highlights berberine’s benefits for blood glucose support, cardiovascular health, and antioxidant activity. It helps lower blood glucose by slowing carbohydrate absorption and enhancing insulin sensitivity, in addition to lowering HbA1c levels. Berberine also reduces waist circumference, body weight, blood pressure, and triglycerides in metabolic syndrome, and lowers total and LDL cholesterol. Improved delivery forms, such as LipoMicel berberine, enhance bioavailability and provide resistance against intestinal degradation, potentially improving intracellular delivery.

Medicinal Ingredients

Each Softgel Contains:

• *Berberine LipoMicel® (hydrochloride) (Berberis vulgaris) (root bark)**: 500 mg

Non-Medicinal Ingredients

• Softgel (gelatin, glycerin, purified water, carob powder)
• Medium chain triglycerides
• Bergamot flavour
• Xylitol
• MSM
• Stevia leaf extract
• Sunflower lecithin

Dosage

• Recommended Adult Dose (18 Years & Older): 1 softgel 2 times per day or as directed by a health care practitioner.
• Duration of Use: Consult a health care practitioner for use beyond 3 months.

Warnings

• Consult a health care practitioner if you have leucopenia, a kidney disorder, or blood pressure problems.
• Consult a health care practitioner prior to use if you have liver disease, hypotension, hypoglycemia, or diabetes.
• Do not use if you are pregnant or breastfeeding.
• May cause gastrointestinal discomfort such as constipation, vomiting, abdominal pain, or diarrhea, in which case discontinue use and consult a health care practitioner.
• Keep out of reach of children.

Allergens

Contains no artificial colours, preservatives, or sweeteners; no dairy, starch, sugar, wheat, gluten, yeast, soy, corn, egg, fish, shellfish, salt, tree nuts, or GMOs.

Contraindications

• Do not use if you are pregnant or breastfeeding.

Drug Interactions

• Berberine may lower blood glucose levels and have an additive effect when combined with other hypoglycemic medications, such as metformin.
• Berberine may increase levels of cyclosporin A, and combined use should be avoided.
• Berberine has inhibitory activity on cytochrome enzymes CYP2D6, 3A4, and CYP2C9, so medications metabolized by these enzymes should be monitored.

References

1. Zhang, H., et al. (2010). Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 59(2), 285-92.
2. Li, Z.Q., et al. (2012). Berberine acutely inhibits the digestion of maltose in the intestine. J Ethnopharmacol, 142(2), 474-80.
3. Hsu, Y.Y., et al. (2013). Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth. Toxicol Appl Pharmacol, 272(3), 787-96.
4. Pérez-Rubio, K.G., et al. (2013). Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord, 11(5), 366-9.
5. Wei, W., et al. (2012). A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol, 166(1), 99-105.
6. Yin, J., et al. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 57(5), 712-.
7. Zhang, Y., et al. (2008). Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab, 93(7), 2559-65.
8. Dong, H., et al. (2013). The effects of berberine on blood lipids: A systemic review and meta-analysis of randomized controlled trials. Planta Med, 79(6), 437-46.
9. Ren, G., et al. (2023). Berberine stimulates lysosomal AMPK independent of PEN2 and maintains cellular AMPK activity through inhibiting the dephosphorylation regulator UHRF1. Front Pharmacol, 14, 1148611.
10. Solnier, J., et al. (2021). Quercetin LipoMicel—A novel delivery system to enhance bioavailability of quercetin. J Nat Health Prod Res, 3(2), 1-8.
11. Chang, C., et al. (2023). A pilot crossover study of berberine and its short-term effects on blood glucose levels in healthy volunteers. J Nat Health Prod Res, 5(2), 1-11.
12. Xin, H.W., et al. (2006). The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol, 28(1), 25-9.
13. Guo, Y., et al. (2012). Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol, 68(2), 213-7.

Visit Pharmacy24.ca to learn more and place your order today!